Clinical trial · Interventional
A Single-Patient Study Using AGS 006
A Single-Patient Study Using AGS 006 as an Immunotherapeutic in a Subject With Newly Diagnosed Resectable Pancreatic Cancer
NCT00664482CI-TRIAL-00009183completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AGS-006 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- AGS-006
- interventionNames
- Biological: AGS-006
Primary outcomes (5)
- measure
- Treatment-emergent changes in vital signs (blood pressure, heart rate, respiratory rate, and body temperature) from baseline values obtained prior to each investigative treatment
- measure
- Incidence of treatment-emergent adverse events graded according to the Common Terminology Criteria for Adverse Events
- measure
- Treatment-emergent adenopathy, tenderness, or inflammation (inguinal and axillary) assessed before and after each dose
- measure
- Treatment-emergent changes in autoimmunity evaluations as measured by clinical signs and symptoms and laboratory assessments at periodic intervals during the Treatment Period.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * A male subject 18 years of age or older with newly diagnosed resectable pancreatic cancer who, in the opinion of the investigator, is suitable for participation in the study will be eligible for inclusion if all of the following criteria apply: 1. Able to abstain from taking prohibited prescription or prohibited non-prescription drugs. 2. Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements. 3. Voluntary informed consent given to participate in the study. Exclusion Criteria: 1. Any serious medical condition such as cardiopulmonary disease, circulatory compromise, hepatic or renal dysfunction, or other illness considered by the investigator to constitute an unwarranted high risk for investigational treatment. 2. Active autoimmune disease including, but not limited to: 3. Active, acute, or chronic clinically significant infections including human immunodeficiency virus (HIV) and viral hepatitis. 4. Known hypersensitivity to dimethyl sulfoxide (DMSO). 5. Body weight less than 30 kg.
References
Publications (0)
Data not yet available
No reference posted for this study.